These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. de Souza CJ; Eckhardt M; Gagen K; Dong M; Chen W; Laurent D; Burkey BF Diabetes; 2001 Aug; 50(8):1863-71. PubMed ID: 11473050 [TBL] [Abstract][Full Text] [Related]
26. Metabolic and additional vascular effects of thiazolidinediones. Martens FM; Visseren FL; Lemay J; de Koning EJ; Rabelink TJ Drugs; 2002; 62(10):1463-80. PubMed ID: 12093315 [TBL] [Abstract][Full Text] [Related]
27. Thiazolidinedione exposure increases the expression of uncoupling protein 1 in cultured human preadipocytes. Digby JE; Montague CT; Sewter CP; Sanders L; Wilkison WO; O'Rahilly S; Prins JB Diabetes; 1998 Jan; 47(1):138-41. PubMed ID: 9421389 [TBL] [Abstract][Full Text] [Related]
28. Novel genes regulated by the insulin sensitizer rosiglitazone during adipocyte differentiation. Albrektsen T; Frederiksen KS; Holmes WE; Boel E; Taylor K; Fleckner J Diabetes; 2002 Apr; 51(4):1042-51. PubMed ID: 11916924 [TBL] [Abstract][Full Text] [Related]
29. Severe but reversible cholestatic liver injury after pioglitazone therapy. Pinto AG; Cummings OW; Chalasani N Ann Intern Med; 2002 Nov; 137(10):857. PubMed ID: 12435231 [No Abstract] [Full Text] [Related]
30. Hepatocellular injury in a patient receiving pioglitazone. Maeda K Ann Intern Med; 2001 Aug; 135(4):306. PubMed ID: 11511159 [No Abstract] [Full Text] [Related]
31. Hepatotoxicity with thiazolidinediones: is it a class effect? Scheen AJ Drug Saf; 2001; 24(12):873-88. PubMed ID: 11735645 [TBL] [Abstract][Full Text] [Related]
32. Increased adipose expression of the uncoupling protein-3 gene by thiazolidinediones in Wistar fatty rats and in cultured adipocytes. Matsuda J; Hosoda K; Itoh H; Son C; Doi K; Hanaoka I; Inoue G; Nishimura H; Yoshimasa Y; Yamori Y; Odaka H; Nakao K Diabetes; 1998 Nov; 47(11):1809-14. PubMed ID: 9792555 [TBL] [Abstract][Full Text] [Related]
33. Isolated elevation of alkaline phosphatase level associated with rosiglitazone. Hachey DM; O'Neil MP; Force RW Ann Intern Med; 2000 Nov; 133(9):752. PubMed ID: 11074926 [No Abstract] [Full Text] [Related]
34. Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Kallen CB; Lazar MA Proc Natl Acad Sci U S A; 1996 Jun; 93(12):5793-6. PubMed ID: 8650171 [TBL] [Abstract][Full Text] [Related]
35. Rosiglitazone, insulin treatment, and fasting correct defective activation of protein kinase C-zeta/lambda by insulin in vastus lateralis muscles and adipocytes of diabetic rats. Kanoh Y; Bandyopadhyay G; Sajan MP; Standaert ML; Farese RV Endocrinology; 2001 Apr; 142(4):1595-605. PubMed ID: 11250941 [TBL] [Abstract][Full Text] [Related]
38. Liver failure in a patient treated with long-term rosiglitazone therapy. Gouda HE; Khan A; Schwartz J; Cohen RI Am J Med; 2001 Nov; 111(7):584-5. PubMed ID: 11705443 [No Abstract] [Full Text] [Related]
39. Failure to develop hepatic injury from rosiglitazone in a patient with a history of troglitazone-induced hepatitis. Lenhard MJ; Funk WB Diabetes Care; 2001 Jan; 24(1):168-9. PubMed ID: 11194222 [No Abstract] [Full Text] [Related]
40. [Diabetes therapy related to etiology. Indications, uses and side effects of new insulin sensitizers]. Ludvik B MMW Fortschr Med; 2000 Jul; 142(28-29):27-8. PubMed ID: 10959156 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]